Your calorie range may not look like someone elses
(Source: Medicare Rights Center, 2026) Medicare Eligibility Criteria State Medicaid Coverage And Why Its Shrinking Medicaid coverage of GLP-1s for obesity is decided state by state, and 2026 brought a notable reversal
Patients seeking GLP-1 therapy should rely on FDA-approved medications with established efficacy profiles, including landmark trials like STEP (semaglutide) demonstrating approximately 15% body weight reduction and SCALE (liraglutide) showing 5-8% weight reduction, along with improved glycemic control in patients with diabetes
No automatic billing or recurring charges will occur
One of the most promising treatments we offer is Semaglutide GLP-1, a glucagon-like peptide-1 (GLP-1) receptor agonist that has shown exceptional effectiveness in facilitating weight loss for overweight or obese adults
Any new or worsening symptoms after months of stable therapy should be evaluated, as these may indicate complications unrelated to expected medication effects
